Allergan (AGN) Tops Q1 EPS by 39c, Offers FY & Q2 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Allergan (AGN) Tops Q1 EPS by 39c, Offers FY & Q2 Guidance
April 30, 2018 1:03 PM EDT
Cantor Fitzgerald lowered its price target on Allergen (NYSE: AGN) to $180.00 (from $191.00) while maintaining a Neutral rating following Q1 results.
Analyst Louise Chen commented, "The decrease in our PT is driven by multiple contraction given a lack of earnings visibility in 2019+ (commercial success... More
April 30, 2018 8:38 AM EDT
Allergan plc (NYSE: AGN) and Medicines360 presented five-year data from their ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, at the American College of Obstetricians and Gynecologists (ACOG) 2018 annual clinical and scientific meeting in Austin, Texas. The abstract presents five-year pregnancy rates (by Pearl Index and life-table analysis) and safety outcomes from the ongoing study. The Pearl Index in the first year, among women who were 1635 years old when they enrolled in the study, was 0.15 (CI: 0.02, 0.55). The cumulative life-table pregnancy rate at 5 years was 0.92 (CI:... More
